Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: USPSTF Recommendation Statement

The US Preventive Services Task Force sets a famously high bar, and this recommendation is a useful demonstration of where that bar sits. On the question of adding three nontraditional tests — the ankle-brachial index, high-sensitivity CRP, and the coronary calcium score — to standard cardiovascular risk assessment, its verdict was a Grade I: insufficient evidence.

The reasoning is subtle and worth understanding, because it is easy to misread as “these tests don’t work.” The Task Force actually acknowledged that all three can improve risk prediction, and that calcium scoring improves it most consistently. What it could not find was the next link in the chain: randomized evidence that acting on these tests — screening asymptomatic people and treating based on the result — actually reduces heart attacks and strokes. Improving a risk estimate is not the same as improving an outcome, and USPSTF demands proof of the latter.

This is the productive tension in the whole calcium-scoring debate. The imaging societies, persuaded by powerful reclassification data, recommend CAC for intermediate-risk patients; the USPSTF, holding out for outcome trials, withholds a verdict. Both are reading the same evidence honestly through different standards of proof. Notably, the Task Force flagged that an update focused on calcium scoring was already underway.

We rate the evidence strong as a recommendation statement — methodologically rigorous and admirably disciplined. Its value to a reader is calibration: it marks the line between a test that sharpens a number and a test proven to change a life, and it is candid that, for now, CAC sits on the near side of that line.